Seer SEER
NASDAQ SEER
$1.95 +0.00 (+0.26%)
As of: Sep 4, 2026 · 1:38 PM EDT

Seer (SEER) Net Income towards Common Stockholders (2020 - 2026)

Seer (SEER) posted quarterly Net Income towards Common Stockholders of -$16.8 million for Q1 2026, up 15.6% year-over-year from -$14.6 million in Q1 2025, and down 5.27% quarter-over-quarter from -$16.0 million in Q4 2025.

Analysis

Seer (SEER) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Seer's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$16.8 million for Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders rose 15.6% year-over-year to -$16.8 million; the TTM figure through Mar 2026 stood at -$70.5 million (up 18.15% YoY), while the FY2025 annual figure was -$73.6 million, up 15.25% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$16.8 million, down from -$16.0 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was -$16.0 million in Q4 2025, with the low at -$66.0 million in Q1 2022.
  • The 5-year median for Net Income towards Common Stockholders is -$22.0 million (2024), against an average of -$29.1 million.
  • The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders tumbled 260.17% in 2022, then soared 67.48% in 2024.
  • Seer's Net Income towards Common Stockholders stood at -$22.5 million in 2022, then increased by 17.86% to -$18.5 million in 2023, then retreated by 18.85% to -$22.0 million in 2024, then advanced by 27.27% to -$16.0 million in 2025, then slipped by 5.27% to -$16.8 million in 2026.
  • Business Quant data shows SEER's Net Income towards Common Stockholders at -$16.8 million in Q1 2026, -$16.0 million in Q4 2025, and -$18.2 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn 472.00 Mn
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - -644.37 Mn
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn - 81.49 Mn
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn -13.27 Mn
10 Seer 107.57 Mn 107.57 Mn 1.51 Mn -16.90 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -16.90 Mn
Mar 31, 2026 -16.84 Mn
Dec 31, 2025 -379,000.00
Sep 30, 2025 -18.23 Mn
Jun 30, 2025 -19.42 Mn
Mar 31, 2025 -19.95 Mn
Dec 31, 2024 -3.48 Mn
Sep 30, 2024 -21.33 Mn
Jun 30, 2024 -22.85 Mn
Mar 31, 2024 -20.68 Mn
Dec 31, 2023 -17.80 Mn
Sep 30, 2023 -21.09 Mn
Jun 30, 2023 -23.43 Mn
Mar 31, 2023 -23.96 Mn
Dec 31, 2022 -22.53 Mn
Sep 30, 2022 -23.98 Mn
Jun 30, 2022 -22.82 Mn
Mar 31, 2022 -23.65 Mn
Dec 31, 2021 -19.74 Mn
Sep 30, 2021 -18.39 Mn